After stumbling through much of 2019, biotechnology ETFs are finding their grooves in the fourth quarter. Since the start of the current quarter, the iShares Nasdaq Biotechnology ETF ( IBB B+ ) is higher by more than 16% while the SPDR S&P Biotech ETF ( XBI B- ) is up 17.40%.